News
By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.
It might be gearing up to pay billions of dollars to participate in a drug program currently in development. AstraZeneca ...
AstraZeneca PLC closed 22.80% short of its 52-week high of £133.88, which the company reached on September 3rd.
The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.
AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...
AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...
AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...
AstraZeneca outperforms markets YTD amid eased concerns, China clarity, minimal US tariff impact, and attractive valuations.
London marked the slowest first half-year for IPO volume since 1997, a grim milestone punctuated by a report that AstraZeneca ...
OPEN The FTSE 100 was expected to open 19.9 points lower on Friday after wrapping up the previous session 0.55% higher at 8,823.20.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback